Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Inclusion Criteria: * Histologically confirmed advanced cancer of any tumor type (Part 1) or NSCLC with a confirmed KRAS mutation as determined by local results (Part 2) * Appropriate candidate for experimental therapy * For patients in Part 2 only: Patient has radiographically measurable disease per RECIST 1.1 criteria. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Adequate cardiac function (Left ventricular ejection fraction (LVEF) ≥50% ) * Adequate organ function * Must have tumor tissue specimen available (optional for patients in Part 1) Exclusion Criteria: * History or current evidence of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues * Current evidence or history of clinically significant corneal or retinal disorder as confirmed by ophthalmologic examination. * Known untreated central nervous system (CNS) metastases or history of uncontrolled seizures. * Significant gastrointestinal disorder(s) that could interfere with absorption of futibatinib/binimetinib * Patients who have neuromuscular disorders that are associated with elevated creatinine kinase (CK)